- Home
- ADAP
as 09-15-2025 4:00pm EST
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
| Founded: | 2008 | Country: | United Kingdom |
| Employees: | N/A | City: | ABINGDON, OXFORDSHIRE |
| Market Cap: | 21.3M | IPO Year: | 2015 |
| Target Price: | $1.02 | AVG Volume (30 days): | 63.5M |
| Analyst Decision: | Hold | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.04 - $1.12 | Next Earning Date: | 11-12-2025 |
| Revenue: | $65,084,999 | Revenue Growth: | -53.99% |
| Revenue Growth (this year): | -77.09% | Revenue Growth (next year): | 52.35% |
Stock Insider Trading Activity of Adaptimmune Therapeutics plc (ADAP)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wood Gavin | ADAP | Chief Financial Officer | Sep 2 '25 | Sell | $0.01 | 96,000 | $950.40 | 0 | |
| Behbahani Ali | ADAP | N/A | Aug 18 '25 | Sell | $0.01 | 14,671,794 | $176,061.53 | 0 | |
| Behbahani Ali | ADAP | N/A | Aug 15 '25 | Sell | $0.01 | 4,828,206 | $53,110.27 | 0 |
Latest Adaptimmune Therapeutics plc News
ADAP Breaking Stock News: Dive into ADAP Ticker-Specific Updates for Smart Investing
MT Newswires
8 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
MT Newswires
11 days ago
European Equities Traded in the US as ADRs Are Little Changed in Friday Trading
MT Newswires
12 days ago
European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading
MT Newswires
3 months ago
Mizuho Downgrades Adaptimmune Therapeutics to Neutral From Outperform, Cuts Price Target to $0.50 From $1.50 on Solvency Concerns
MT Newswires
3 months ago
European Equities Traded in the US as American Depositary Receipts Fall in Wednesday Trading
MT Newswires
3 months ago
European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading
MT Newswires
3 months ago
European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
GuruFocus.com
4 months ago
Adaptimmune Therapeutics PLC (ADAP) Q1 2025 Earnings Call Highlights: Strong Tecelra Launch ...
Compare ADAP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ADAP Adaptimmune Therapeutics plc - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.